12 June 2024 : Reference is made toAker BioMarine ASA's stock exchange announcement on6 May 2024 , regarding the result of the offer under the Employee Share Purchase Program and the related share capital increase. The share capital increase pertaining to the Employee Share Purchase Program has today been registered with theNorwegian Register ofBusiness Enterprises (Nw.: Foretaksregisteret). The new registered share capital of the company isNOK 526 110 084 divided into 87 685 014 shares, each with a par value ofNOK 6.00 . Upon registration with theNorwegian Central Securities Depository (VPS), the new shares will be listed on theOslo Stock Exchange . This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. For further information, please contactKatrine Klaveness CFO Mobile: +47 991 58 915 Email: Katrine.Klaveness@akerbiomarine.com AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source